Dual IO 2021 Year in Review
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma. Read More ›
Durvalumab plus standard-of-care chemotherapy and durvalumab with tremelimumab plus standard-of-care chemotherapy were both associated with better progression-free survival compared with standard-of-care chemotherapy alone in the treatment of metastatic NSCLC. Read More ›
Nivolumab plus ipilimumab combined with 2 cycles of chemotherapy for the treatment of advanced NSCLC demonstrates durable efficacy compared with 4 cycles of chemotherapy alone in a 2-year follow-up study. Read More ›
After more than 4 years of follow-up, patients with advanced NSCLC treated with nivolumab plus ipilimumab maintained overall survival rates. Read More ›
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC. Read More ›